Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

eed to make up to $80 million in additional base and contingent payments.

Revenues:  Lexicon's revenues for the three months ended September 30, 2010 decreased 63 percent to $0.8 million from $2.1 million for the corresponding period in 2009.  The decrease for the three months ended September 30, 2010 was primarily attributable to reduced revenues under Lexicon's alliance agreements with Taconic Farms and Bristol-Myers Squibb Company.  For the nine months ended September 30, 2010, revenues decreased 61 percent to $3.7 million from $9.3 million for the corresponding period in 2009.

Research and Development Expenses:  Research and development expenses for the three months ended September 30, 2010 increased four percent to $20.1 million from $19.3 million for the corresponding period in 2009.  For the nine months ended September 30, 2010, research and development expenses decreased two percent to $61.4 million from $62.4 million for the corresponding period in 2009.

General and Administrative Expenses:  General and administrative expenses for the three months ended September 30, 2010 increased eight percent to $4.9 million from $4.6 million for the corresponding period in 2009.  The increase was primarily attributable to increases in salary and benefit costs.  For the nine months ended September 30, 2010, general and administrative expenses increased four percent to $15.5 million from $15.0 million for the corresponding period in 2009.

Net Loss Attributable to Lexicon Pharmaceuticals, Inc.:  Net loss for the three months ended September 30, 2010 was $27.5 million, or $0.08 per share, compared to a net loss of $19.1 million, or $0.14 per share, in the corresponding period in 2009.  Net loss for the nine months ended September 30, 2010 was $78.8 million, or $0.27 per share, compared to a net loss of $60.8 million, or $0.44 per share, for the corresponding period
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... the stress of the Second Lebanon War suffered fewer attacks ... focusing on feelings. This has been shown in a new ... the Technion-Israel Institute of Technology and Carmel Medical Center. "Because ... is important to uncover all the factors that impact the ...
... biggest Roman candle has got nothing on this. Using ... Earth or on a giant planet, Washington State University ... storing vast amounts of energy. "If you think about ... storage outside of nuclear energy," says Choong-Shik Yoo, a ...
... A major breakthrough in remote wave sensing by a ... for detecting hidden explosives, chemical, biological agents and illegal ... new, all-optical system, using terahertz (THz) wave technology, has ... it can "see through" clothing and packaging materials and ...
Cached Biology Technology:Can multiple sclerosis attacks be minimized in a war zone? 2A revolutionary breakthrough in terahertz remote sensing 2
(Date:4/18/2014)... Peru found that 28 percent of the batches ... Many pills released the active ingredient too slowly. ... had no active ingredient at all. , ... Georgia Institute of Technology developed a sophisticated approach ... drugs and then characterize their chemical composition. The ...
(Date:4/18/2014)... population predicted to reach 9 billion by 2050 ... considers human-altered landscapes such as farmland, according to ... that supports it might be an increasingly scarce ... of the land surface is directly affected by ... impacts such as climate change. But what if ...
(Date:4/18/2014)... Ancient DNA adds a twist to the story of ... be published April 21 in the journal Proceedings of ... the bones of chickens that lived 200-2300 years ago in ... domestic chickens may have looked far different from the chickens ... the traits we associate with modern domestic chickens -- such ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Ancient DNA offers clues to how barnyard chickens came to be 2
... , This release is available in ... thinks of herbal teas or valerian drops. However, that ... the Fraunhofer Institute for Molecular Biology and Applied Ecology ... to produce biopharmaceuticals. Those are proteins that, unlike many ...
... competitive realm of bacteria, cheaters must be kept in ... that in one bacterium, at least, bacterial cooperators can ... for dominance. "Even simple organisms such as ... Velicer, who with Ph.D. student Pauline Manhes has reported ...
... with rheumatoid arthritis are two times more likely to ... controls -- an association which was sustained even when ... controlled for, according to a study presented today at ... 15,766 patients with RA and 15,340 controls found that ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... Moto Alpha unit with motorized heated lid and ... is useful for microarrays and chips. The four ... The sealing force of the motorized lid is ... give repeatable results. This interchangeable Moto Alpha unit ...
... Anti-Krueppel-like factor 15 (KLF15) KLF15 is ... found abundantly expressed in the liver, kidneys, ... NP_054798 Specificity: Polyclonal antibody produced in ... to a region of human KLF15 with ...
... For affinity chromatography, Affi-Prep protein ... (IgG), selectively remove IgG prior to ... adsorb immune complexes for antigen purification. ... region of immunoglobulins, especially IgG from ...
Biology Products: